Iradimed (IRMD) director reports 905-share acquisition from RSU conversion

Rhea-AI Filing Summary

Iradimed Corporation director Hilda Scharen-Guivel reported acquiring 905 shares of common stock through the conversion of restricted stock units. The transaction on December 11, 2025 is coded "M", indicating an exercise or conversion of derivative securities, and increased her directly held common stock to 8,598 shares. A related entry in the derivative table shows 905 restricted stock units converting into 905 common shares at an exercise price of $0, leaving 906 restricted stock units beneficially owned. The restricted stock units were granted under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025, with shares of common stock delivered as each installment vests.

Insider Trade Summary

905 shares exercised/converted

Mixed 2 txns

Insider Scharen-Guivel Hilda Frederique

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	905	$0.00	--
Exercise	Common Stock	905	$0.00	--

Holdings After Transaction: Restricted Stock Units — 906 shares (Direct); Common Stock — 8,598 shares (Direct)

Footnotes (1)

1. Restricted stock units convert into common stock on a one-for-one basis. On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scharen-Guivel Hilda Frederique

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		905	A	(1)	8,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/11/2025		M			905	(2)	(2)	Common Stock	905	$0	906	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On December 11, 2024, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

	/s/ Hilda Scharen-Guivel	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Iradimed (IRMD) report for December 11, 2025?

Iradimed reported that director Hilda Scharen-Guivel converted 905 restricted stock units into 905 shares of common stock in a transaction coded "M" on December 11, 2025.

How many Iradimed (IRMD) shares does the director own after this Form 4 transaction?

After the reported transaction, the director beneficially owns 8,598 shares of Iradimed common stock directly.

What happened to the restricted stock units (RSUs) in this Iradimed (IRMD) filing?

905 restricted stock units converted into 905 shares of common stock at an exercise price of $0, and 906 restricted stock units remain beneficially owned.

Under which equity plan were the Iradimed (IRMD) RSUs granted?

The restricted stock units were granted under Iradimed Corporation's 2023 Equity Incentive Plan.

How do the Iradimed (IRMD) restricted stock units vest for this director?

The restricted stock units granted on December 11, 2024 vest in two equal annual installments beginning on December 11, 2025, with shares of common stock delivered as each portion vests.